Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
Meridian Growth Fund highlighted stocks like Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), in the second quarter 2024 investor letter. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company that develops medicines in the field of cellular metabolism. The one-month return of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was 1.20%, and its shares gained 81.13% of their value over the last 52 weeks. On September 16, 2024, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stock closed at $45.41 per share with a market capitalization of $2.584 billion. Meridian Growth Fund stated the following regarding Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in its Q2 2024 investor letter: "Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a leader in cellular metabolism and pyruvate kinase activation pioneering therapies for rare diseases. The stock appreciated in the quarter after it announced positive Phase 3 testing results of mitapivat, a therapy for adults with non-transfusion dependent thala
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.MarketBeat
- Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals' tebapivat gains FDA orphan drug designation [Yahoo! Finance]Yahoo! Finance
- Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)GlobeNewswire
- Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024GlobeNewswire
AGIO
Earnings
- 8/1/24 - Miss
AGIO
Sec Filings
- 8/13/24 - Form 4
- 8/13/24 - Form 4
- 8/12/24 - Form 4
- AGIO's page on the SEC website